ENDURING CUSTOMER
RELATIONSHIPS
Market-leading products and services combined
with strategic acquisitions position Invitrogen
well for the future. None of this technological
capability matters, however, unless we have the
support of our customers. That’s why we
strive to be more than just a supplier. Our goal
is to be an essential partner.
Every day hundreds of Invitrogen technical sales
people consult with scientists worldwide to understand
their needs. Often, we are conduits for new scientific
advancements made somewhere across the globe.
At other times, we are advisors recommending new
tools that will take a research project to the
next step. In Hong Kong, a researcher might discover
how our LUX™ primers can facilitate her
work on SARS. In London, a lab technician might
learn that E-PAGE™ 96 gels are exactly what
he needs to analyze proteins. And in New York,
a graduate student might discover just how easy
it is to clone a gene with our Gateway Technology.
These discussions occur every day across the globe.
They are the lifeblood of our company. They are
the product of trust. And they are as important
to a customer’s research as they are to
our company’s success. Some of our biggest
ideas have come from these intimate conversations
about science, a researcher’s needs, and
how we can help. Preserving this trust between
Invitrogen and its customers is paramount to all
our employees. We listen, understand, and take
the action necessary to meet their needs and move
research forward.
Listening to our customers guided us to introduce
a new licensing policy for our market-leading
Gateway Technology in November. Previously, customers
who purchased Gateway were restricted in their
ability to clone genes and conduct downstream
experiments with those clones. Under the premise
that a less restricted approach would encourage
more research, we created Gateway open architecture.
Under the new policy, researchers who purchase
Gateway can create and freely distribute clones
within the scientific community so that others
may learn from their work to further our understanding
of life. In the world of science, knowledge is
built by sharing information. Kevin Auton, chief
executive officer of NextGen Sciences in Cambridgeshire,
United Kingdom, strongly believes this too, as
he remarked, “By opening access to Gateway
Technology, many research groups and commercial
suppliers will now be able to create gene libraries
and distribute these as a resource for all researchers.
We at NextGen Sciences applaud Invitrogen for
this bold step and anticipate that Gateway will
become the industry standard in gene cloning and
protein expression.”
Gateway Technology is now available to serve
as the common language for functional biology.
By using our clone collection or another created
by researchers worldwide, scientists now have
a universal tool to study genes or proteins and
the role they play in disease or potential therapies.
When our technologies enable research results
and make the difficult possible, we know we’re
accelerating biological understanding. We know
we’re making a difference. |